Literature DB >> 23017679

Improvement of protein immobilization for the elaboration of tumor-associated antigen microarrays: application to the sensitive and specific detection of tumor markers from breast cancer sera.

Zhugen Yang1, Yann Chevolot, Thomas Géhin, Jérôme Solassol, Alain Mange, Eliane Souteyrand, Emmanuelle Laurenceau.   

Abstract

There is an urgent need to identify relevant tumor markers showing high sensitivity and specificity for early diagnosis and prognosis of breast cancer. Protein microarrays have demonstrated to be cost-effective, high through-put and powerful tools for screening and identifying tumor markers with only minute samples. Autoantibodies directed against tumor-associated antigens (TAAs) were shown to be relevant tumor markers. However, due to the variability of immune response from one individual to another and depending on the type of cancer, detection of only one type of anti-TAA autoantibody is not sufficient to give a reliable and precise diagnosis. It is necessary to use a set of several TAAs for determining specific autoimmune profiles. Therefore, combining various TAAs on different surfaces could improve sensitivity and specificity for anti-TAA autoantibody detection. Herein a panel of 10 proteins, including well-known tumor-associated antigens (TAAs) and potential new biomarkers of breast cancer, were immobilized onto microstructured microarray under optimized conditions (spotting pH buffer, surface chemistry, blocking procedure), in order to determine an autoimmune signature of breast cancer. Sera from 29 breast cancer patients and 28 healthy donors were screened in sandwich immunoassays on the miniaturized system to detect the eventual presence of anti-TAAs autoantibodies. Results indicated that the detection level of each anti-TAA autoantibody in a given serum sample was strongly dependant on the surface chemistry. Combining five TAAs (p53, Hsp60, Hsp70, Her2-Fc, NY-ESO-1) on two different surface chemistries (NHS and APDMES) allowed the significant detection of more than 82% breast cancer sera.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23017679     DOI: 10.1016/j.bios.2012.08.019

Source DB:  PubMed          Journal:  Biosens Bioelectron        ISSN: 0956-5663            Impact factor:   10.618


  10 in total

1.  NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.

Authors:  Yoko Oshima; Hideaki Shimada; Satoshi Yajima; Tatsuki Nanami; Kazuyuki Matsushita; Fumio Nomura; Osamu Kainuma; Nobuhiro Takiguchi; Hiroaki Soda; Takeshi Ueda; Toshihiko Iizasa; Naoto Yamamoto; Hiroshi Yamamoto; Matsuo Nagata; Sana Yokoi; Masatoshi Tagawa; Seiko Ohtsuka; Akiko Kuwajima; Akihiro Murakami; Hironori Kaneko
Journal:  J Gastroenterol       Date:  2015-04-24       Impact factor: 7.527

2.  Expression and immunogenicity of NY-ESO-1 in colorectal cancer.

Authors:  Ya Li; Ruifeng Song; Xinqiang Li; Feng Xu
Journal:  Exp Ther Med       Date:  2017-04-28       Impact factor: 2.447

3.  Cancer-Testis Gene Biomarkers Discovered in Colon Cancer Patients.

Authors:  Mikhlid H Almutairi; Turki M Alrubie; Abdullah M Alamri; Bader O Almutairi; Abdulwahed F Alrefaei; Maha M Arafah; Mohammad Alanazi; Abdelhabib Semlali
Journal:  Genes (Basel)       Date:  2022-05-01       Impact factor: 4.141

Review 4.  Use of autoantibodies to detect the onset of breast cancer.

Authors:  Jérôme Lacombe; Alain Mangé; Jérôme Solassol
Journal:  J Immunol Res       Date:  2014-07-21       Impact factor: 4.818

5.  Immune-Signatures for Lung Cancer Diagnostics: Evaluation of Protein Microarray Data Normalization Strategies.

Authors:  Stefanie Brezina; Regina Soldo; Roman Kreuzhuber; Philipp Hofer; Andrea Gsur; Andreas Weinhaeusel
Journal:  Microarrays (Basel)       Date:  2015-04-02

6.  Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers.

Authors:  Isamu Hoshino; Yoshihiro Nabeya; Nobuhiro Takiguchi; Hisashi Gunji; Fumitaka Ishige; Yosuke Iwatate; Fumiaki Shiratori; Satoshi Yajima; Rei Okada; Hideaki Shimada
Journal:  Ann Gastroenterol Surg       Date:  2020-03-25

7.  Immunoproteomics approach revealed elevated autoantibody levels against ANXA1 in early stage gallbladder carcinoma.

Authors:  Javed Akhtar; Ratna Priya; Vaishali Jain; Puja Sakhuja; Anil Kumar Agarwal; Surbhi Goyal; Ravindra Varma Polisetty; Ravi Sirdeshmukh; Sudeshna Kar; Poonam Gautam
Journal:  BMC Cancer       Date:  2020-12-01       Impact factor: 4.430

Review 8.  Tumor-associated autoantibodies as diagnostic and prognostic biomarkers.

Authors:  Chang-Kyu Heo; Young Yil Bahk; Eun-Wie Cho
Journal:  BMB Rep       Date:  2012-12       Impact factor: 4.778

9.  Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.

Authors:  Rick L Evans; James V Pottala; Satoshi Nagata; Kristi A Egland
Journal:  BMC Cancer       Date:  2018-01-31       Impact factor: 4.430

Review 10.  NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.

Authors:  Remy Thomas; Ghaneya Al-Khadairi; Jessica Roelands; Wouter Hendrickx; Said Dermime; Davide Bedognetti; Julie Decock
Journal:  Front Immunol       Date:  2018-05-01       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.